| [ Summary ] |
CKD-MBD-related drugs, such as phosphate binder, vitamin D receptor activator, and cinacalcet hydrochloride, represent a large proportion of prescription drugs used in dialysis patients and contribute to polypharmacy. Mortality should be prioritized when selecting medicines, and it is crucial to manage serum phosphate level appropriately in CKD-MBD. Multiple phosphate binders are necessary for good phosphate control, rather than single-drug treatment. When prescribing these drugs, purgative or antiemetic medicines are concomitantly used for drug-induced constipation or nausea, which leads to further polypharmacy. In this report, polypharmacy for CKD-MBD-related agents are considered from the viewpoint of both risk and benefit. |